Memantine inhibits cortical spreading depolarization and improves neurovascular function following repetitive traumatic brain injury

Sci Adv. 2023 Dec 15;9(50):eadj2417. doi: 10.1126/sciadv.adj2417. Epub 2023 Dec 13.

Abstract

Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals (N = 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial.

Publication types

  • Randomized Controlled Trial, Veterinary

MeSH terms

  • Animals
  • Brain / metabolism
  • Brain Injuries, Traumatic* / drug therapy
  • Electrocorticography
  • Memantine* / pharmacology
  • Rats
  • Receptors, N-Methyl-D-Aspartate / metabolism

Substances

  • Memantine
  • Receptors, N-Methyl-D-Aspartate